Advances of mRNA vaccine in tumor: a maze of opportunities and challenges.
Biomark Res
; 11(1): 6, 2023 Jan 18.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2196486
ABSTRACT
High-frequency mutations in tumor genomes could be exploited as an asset for developing tumor vaccines. In recent years, with the tremendous breakthrough in genomics, intelligence algorithm, and in-depth insight of tumor immunology, it has become possible to rapidly target genomic alterations in tumor cell and rationally select vaccine targets. Among a variety of candidate vaccine platforms, the early application of mRNA was limited by instability low efficiency and excessive immunogenicity until the successful development of mRNA vaccines against SARS-COV-2 broken of technical bottleneck in vaccine preparation, allowing tumor mRNA vaccines to be prepared rapidly in an economical way with good performance of stability and efficiency. In this review, we systematically summarized the classification and characteristics of tumor antigens, the general process and methods for screening neoantigens, the strategies of vaccine preparations and advances in clinical trials, as well as presented the main challenges in the current mRNA tumor vaccine development.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Tipo de estudio:
Estudio pronóstico
Tópicos:
Vacunas
Idioma:
Inglés
Revista:
Biomark Res
Año:
2023
Tipo del documento:
Artículo
País de afiliación:
S40364-023-00449-w
Similares
MEDLINE
...
LILACS
LIS